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Abstract
Background: Traditionally tricyclic antidepressants (TCAs) have an important place in treatment of major depressive
disorder (MDD). Today, often other antidepressant medications are considered as first step in the pharmacological
treatment of MDD, mainly because they are associated with less adverse effects, whereby the position of TCAs appears
unclear. In this study we aimed to examine the current practice of TCAs in treatment of unipolar MDD.
Methods: A mixed methods approach was applied. First, a selection of leading international and national guidelines
was reviewed. Second, actual TCA prescription was examined by analyzing health records of 75 MDD patients treated
with the TCAs nortriptyline, clomipramine or imipramine in different centers in the Netherlands. Third, promotors and
barriers influencing the choice for TCAs and dosing strategies were explored using semi-structured interviews with 24
Dutch psychiatrists.
Results: Clinical practice guidelines were sometimes indirective and inconsistent with each other. Health records
revealed that most patients (71%) attained therapeutic plasma concentrations within two months of TCA use. Patients
who achieved therapeutic plasma concentrations reached them on average after 19.6 days (SD 10.9). Both health
records and interviews indicated that therapeutic nortriptyline concentrations were attained faster compared to other
TCAs. Various factors were identified influencing the choice for TCAs and dosing by psychiatrists.
Conclusions: Guideline recommendations and clinical practice regarding TCA prescription for MDD vary. To increase
consistency in clinical practice we recommend development of an up-to-date guideline integrating selection and
dosing of TCAs, including the roles of therapeutic drug monitoring and pharmacogenetics. Such a guideline is
currently lacking and would contribute to optimal TCA treatment, whereby efficacy and tolerability may be increased.
Keywords: Antidepressant agents, Clinical practice guidelines, Qualitative approach, Major depressive disorder, Tricyclic
antidepressants
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Introduction
Major depressive disorder (MDD) is among the leading
causes of disability worldwide with a lifetime risk of 15 to
18% and over 264 million people affected globally [1, 2].
MDD is commonly treated with antidepressant medica-
tions, such as tricyclic antidepressants (TCAs), selective
serotonin reuptake inhibitors (SSRIs) and serotonin-
noradrenaline reuptake inhibitors (SNRIs). TCAs have
been of foremost importance in pharmacotherapy of
MDD since their introduction in the 1950s [3]. However,
over the last decades, SSRIs, SNRIs and other modern an-
tidepressants are increasingly considered as first-line
agents, mainly because they are associated with less ad-
verse effects and since they are less dangerous in overdose
[3–6]. TCAs continue to be prescribed, if only because of
the common occurrence of non-response to SSRIs and
SNRIs, but the current position of TCAs in pharmaco-
therapy of unipolar MDD is unclear [3, 4].
An advantage of TCAs over SSRIs and SNRIs is that
therapeutic plasma concentrations associated with optimal
efficacy are defined [7]. Subtherapeutic concentrations are
related to suboptimal or non-response whereas suprather-
apeutic concentrations are associated with higher rates of
adverse effects. Importantly, there are considerable inter-
individual differences between TCA doses administered
and plasma concentrations achieved, notably because of
variation in activity of the cytochrome P-450 (CYP) en-
zymes by which TCAs are metabolized [8]. During TCA
treatment plasma concentrations can be monitored to
guide dosing until an adequate maintenance dose is
reached (therapeutic drug monitoring; TDM) [7].
So far, it has not been investigated what factors influ-
ence the choice for TCAs instead of other antidepressants
by psychiatrists. As a result, the present-day significance
of TCAs in pharmacotherapy of MDD remains unclari-
fied. Also, it is unknown how long it takes until thera-
peutic TCA plasma concentrations are attained, which
impairs the ability to determine to what extent novel dos-
ing strategies, such as genotype-informed dosing, may ac-
celerate TCA dose-adjustment [8, 9].
The aim of this study was to examine the current
practice of TCA treatment for adult patients with
unipolar MDD. Our objectives were to assess guide-
line recommendations on TCA treatment, to investi-
gate real-world TCA prescription and to gain
understanding of underlying factors influencing TCA
selection and dosing by psychiatrists. It was hypothe-
sized that TCA prescription was highly influenced by
individual preferences of psychiatrists, rather than a
straightforward application of the guidelines. This
would be problematic, since variation in antidepres-
sant prescription suggests suboptimal treatment for at
least a subgroup of patients.
Methods
Study design
Since we aimed to investigate guideline recommenda-
tions, actual TCA treatment and factors influencing
TCA prescription by psychiatrists, a mixed methods ap-
proach was used. First, recommendations from anti-
depressant prescribing guidelines were examined
because it was assumed that these were leading for TCA
prescription in clinical practice. Second, health records
were analysed of MDD patients treated with TCAs to
examine actual TCA prescription. Third, promotors and
barriers influencing TCA treatment were explored by
conducting semi-structured interviews with psychiatrists.
In this study, the TCAs nortriptyline, clomipramine,
imipramine and amitriptyline were investigated, as these
are commonly prescribed and recommended in treat-
ment of MDD in the Netherlands [10]. Amitriptyline
was not included in the analysis of health records since
particularly this TCA is often prescribed for other indi-
cations, such as neuropathic pain, which could be diffi-
cult to distinguish in health records [11].
Guideline recommendations
To provide an overview of guideline directions two leading
European, two North-American, two international (global)
and the Dutch national guideline on treatment of MDD were
reviewed, as presented in Table 1. Guidelines were selected
considering their relevance for TCA prescription in a Dutch
setting with the consensus of all authors.
In addition, summaries of product characteristics
(SmPC) of nortriptyline, clomipramine, imipramine and
amitriptyline were reviewed. In absence of SmPCs by the
European Medicines Agency, we only reviewed those ap-
proved by the Dutch Medicines Evaluation Board [19–
22] and the United States Food and Drug Administra-
tion [23–26]. Furthermore, international consensus
guidelines on TDM and pharmacogenetics were selected
and reviewed [7, 8].
Health records
To investigate actual TCA prescription, 75 health re-
cords were analyzed of MDD patients treated with nor-
triptyline, clomipramine or imipramine divided over five
centers in the Netherlands. The centers included one
academic hospital (Radboudumc, Nijmegen), one general
hospital (Catharina Hospital, Eindhoven) and three large
psychiatric institutions (Pro Persona, Nijmegen; Vincent
van Gogh, Venray; Dimence Group, Deventer). Permis-
sion was obtained from ethical review boards or boards
of directors for each center.
In each center 15 records were selected randomly.
First, all adult patients treated with nortriptyline, clo-
mipramine or imipramine between January 2014 and
June 2018 were extracted from the electronic
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institutional system. Second, records were selected in
the order of a random numbers list generated in SPSS
version 26 (IBM Corp, Armonk, NY) until 15 suitable
records were selected per center. Inclusion criteria were
treatment with nortriptyline, clomipramine or imipra-
mine for unipolar MDD, diagnosed according to DSM-
IV-TR or DSM-5 criteria [27, 28], and TCA use for at
least four consecutive weeks. An exclusion criterium was
participation in scientific research influencing TCA pre-
scription. Dosing was analyzed during the first 2 months
of TCA use. Selection and dosing characteristics were
compared between the TCAs using X2-tests or one-way
ANOVA where appropriate.
Semi-structured interviews
Semi-structured interviews were conducted to identify fac-
tors influencing TCA prescription in clinical practice. An
interview guide was developed by the authors and based
on the model of Flottorp et al. [29] (Supplement 1). Psy-
chiatrists were selected varying in gender, years of profes-
sional experience, center (a maximum of two psychiatrists
per center), type of center (academic hospital, general hos-
pital, general psychiatric institution or private practice
holder), setting (hospitalized versus outpatient) and geo-
graphical location in the Netherlands. An inclusion crite-
rium was TCA prescription for MDD at least once per 3
months over the last year.
Interviews were held face-to-face by two interviewers
(CV and MOdC), either on location or by videocall, be-
tween July and September 2020. Permission for audio-
recording and use of data was obtained from all psychia-
trists. Interviews were held until no new information
was identified. Subsequently, interviews were transcribed
verbatim and coded and analyzed in Atlas by both inter-
viewers (Atlas.ti 8.4.20, Windows).
Results
Guideline recommendations on TCA selection
To examine guideline directions on TCA prescription,
selected antidepressant prescribing guidelines and TCA
product characteristics were reviewed. Clinical practice
guideline recommendations on TCA selection are sum-
marized in Table 2. All reviewed guidelines consider the
overall efficacy of TCAs, SSRIs and SNRIs comparable.
Also, they agree that TCAs are associated with more ad-
verse effects and that they are more dangerous in over-
dose. Therefore, the National Institute for Health and
Care Excellence (NICE), American Psychiatric Associ-
ation (APA) and Canadian Network for Mood and Anx-
iety Treatments (CANMAT) recommend TCAs as
second- or third-line treatment options [12, 14, 15].
Guidelines by the World Health Organization (WHO),
World Federation of Societies of Biological Psychiatry
(WFSBP), Deutsche Gesellschaft für Psychiatrie, Psy-
chotherapie und Nervenheilkunde (DGPPN) and the
Dutch guideline state no general preference between
TCAs, SSRIs, SNRIs and the other modern antidepres-
sants mirtazapine and bupropion, except for subgroups
of patients [10, 13, 16–18]. The WHO advises TCAs or
the SSRI fluoxetine during pregnancy [16], the DGPPN
advises TCAs in patients with comorbid pain syndrome
[13] and the Dutch guideline recommends TCAs in
psychotic depression and in hospitalized MDD patients
[10, 18]. Concerning elderly patients, the WHO, WFSBP
and Dutch guideline prefer SSRIs over TCAs [16–18]. If
a TCA is selected in elderly patients, generally nortripty-
line is preferred as it is associated with the least adverse
effects among the TCAs [13, 14, 17, 18]. Several guide-
lines recommend clomipramine in patients with a co-
morbid anxiety disorder or obsessive-compulsive
disorder (OCD) because of its serotonergic profile [10,
15, 17].
Apart from SSRIs, SNRIs, TCAs, mirtazapine and bu-
propion, first- and second-line treatment options may
Table 1 Selected clinical practice guidelines on the pharmacological treatment of unipolar MDD
Guideline Country
Depression in Adults: Recognition and Management, by the National Institute for Health and Care Excellence (NICE), 2020 [12] England
Unipolare Depression, by the Deutsche Gesellschaft für Psychiatrie, Psychotherapie und Nervenheilkunde (DGPPN), 2015 [13] Germany
Practice Guideline for the Treatment of Patients with Major Depressive Disorder, by the American Psychiatric Association (APA), 2010
[14]
United States
Clinical Guidelines for the Treatment of Major Depressive Disorder, by the Canadian Network for Mood and Anxiety Treatments
(CANMAT), 2016 [15]
Canada
Antidepressants in Treatment of Adults with Depression, by the World Health Organization (WHO), 2012 [16] Global
World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for Biological Treatment of Unipolar Depressive Disorder,
2013 [17]
Global
Multidisciplinary Guideline for Treatment of Depressive Disorders, by the Trimbos Institute, 2013 [10]; including the Addendum for
Treatment of Elderly Patients, Trimbos Institute, 2008 [18]
The
Netherlands
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include other antidepressant medications, such as multi-
modal antidepressants which combine different modes
of action, e.g. vortioxetine and agomelatine [15, 30].
Also, a number of guidelines consider combining antide-
pressants or augmentation with other psychopharmaceu-
ticals, in particular antipsychotics, as second-line
treatment option.
Summaries of TCA product characteristics highlight
contra-indications for TCAs, particularly recent myocar-
dial infarction and co-use of monoamine oxidase (MAO)
inhibitors [19–26]. The reviewed documents on TDM and
pharmacogenetics do not consider TCA selection [7, 8].
Guideline recommendations on TCA dosing
Directions on TCA dosing are presented in Table 3. All
selected guidelines advise to start with a lower, non-
therapeutic dosage to minimize adverse effects and to
prevent early discontinuation. Subsequently, the dose
should be increased gradually until an adequate main-
tenance dose is reached.
The NICE guideline recommends a lower initial TCA
dosage in case of switching from fluoxetine or paroxe-
tine since these SSRIs influence TCA plasma concentra-
tions [12]. Also, the NICE advises to maintain and no
longer increase the TCA dosage if treatment response
occurs [12]. All guidelines agree that dosing in elderly
patients should be more gradual. Furthermore,
hospitalization and cardiovascular disease may affect the
dosing strategy, as shown in Table 3.
Most guidelines advise TDM in case of non-response
[10, 13, 14, 18]. The DGPPN strongly recommends
TDM during TCA up-titration in general and particu-
larly in patients with non-response, adverse effects, if the
maximum dose is used, if comedications are prescribed
or in case of comorbidities [13]. The Dutch guideline ad-
vises TDM in case of non-response and in elderly pa-
tients with severe depression [10, 18].
TCA metabolization is influenced by activity of rele-
vant cytochrome P-450 (CYP) enzymes, depending
on the patients' genotype, which results in interindivid-
ual differences in the relation between TCA dose admin-
istered and plasma concentration achieved [8]. For poor,
intermediate and ultra-rapid metabolizers of CYP2D6
and CYP2C19, genotype-informed dosing recommenda-
tions are available [8]. Several selected documents con-
sider pharmacogenetics to personalize TCA dosing but
none indicates explicitly when pharmacogenetic testing
should be applied. The CANMAT dissuades routine
pharmacogenetic testing [15].
TCA prescription in clinical practice
To investigate TCA prescription in clinical practice, 75
health records were examined of MDD patients treated
with nortriptyline (n = 53, 71%), clomipramine (n = 18,
24%) or imipramine (n = 4, 5%), as presented in Table 4.
Most patients older than 65 years were treated with nor-
triptyline. Patients with comorbid anxiety, defined as
MDD with anxious distress or MDD with a comorbid
anxiety disorder, were treated with nortriptyline (n = 5)
or clomipramine (n = 2).
Dosing was analyzed regarding the first 2 months of
TCA use. Initial and maximum doses differed between
Table 2 Clinical guideline recommendations on TCA selection in pharmacotherapy of unipolar MDD
Institute, year Position of TCAs§ Preference between NOR, CLO, IMI
and AMI†
NICE, 2020 [12] First-line: SSRI. First switch to another modern antidepressant prior to
venlafaxine, TCA or monoamine oxidase inhibitor.
No preference.
DGPPN, 2015 [13] First-line options include SSRIs, SNRIs and TCAs. Comorbid diabetes
mellitus: no sedative TCA.
Comorbid pain syndrome: TCA.
NOR: least adverse effects.
Avoid CLO in combination with
monoamine oxidase inhibitors.
APA, 2010 [14] First-line: SSRI SNRI, mirtazapine or bupropion. Second-line treatment op-
tions include TCAs.
NOR: elderly patients, Parkinson’s
disease, smoking cessation.
CANMAT, 2016 [15] First-line: SSRI, SNRI, mirtazapine, bupropion, agomelatine, mianserin,
milnacipran, vortioxetine.
Second-line options include TCAs.
CLO: MDD with anxious distress.
WHO, 2012 [16] First-line options include SSRIs, SNRIs and TCAs.
Elderly patients: SSRI. During pregnancy: TCA or fluoxetine.
No preference.
WFSBP, 2013 [17] First-line: SSRI, bupropion or mirtazapine in mild depression and SSRI,
SNRI or TCA in severe depression.




Guideline, 2013, 2008 [10, 18]
First-line: SSRI, SNRI, mirtazapine or bupropion.
Hospitalized patients: TCA. Elderly patients: SSRI.
Psychotic depression: TCA.
NOR: elderly patients.
CLO: comorbid anxiety disorder, OCD.
§ Position of TCAs relative to other first- or second-line options in the pharmacological treatment of unipolar major depressive disorder (MDD)
† NOR = nortriptyline, CLO = clomipramine, IMI = imipramine, AMI = amitriptyline
¶ Obsessive-compulsive disorder
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the TCAs in accordance with guideline recommenda-
tions (see Table 3). Pharmacogenetics was applied in five
patients (7%) to personalize TCA dosing. Within the
first 2 months of treatment, TDM was applied in 67 pa-
tients (89%). In total, 53 patients (71%) attained thera-
peutic plasma concentrations, on average after 19.6 days
(SD 10.9). For nortriptyline, 42 patients (79%) reached
therapeutic plasma concentrations, averagely after 17.2
days (SD 8.1). Nine patients using clomipramine (50%)
attained therapeutic plasma concentrations, on average
after 25.6 days (SD 14.9) and two patients treated with
imipramine (50%) reached therapeutic plasma concen-
trations, on average after 43.5 days (SD 0.7).
The number of patients attaining therapeutic plasma
concentrations differed significantly between the TCAs,
X2 (1, n = 75) = 6.415, p = 0.040. Considering the 67 pa-
tients for whom TDM was applied, patients treated with
nortriptyline reached therapeutic plasma concentrations
more frequently compared to patients using either clo-
mipramine or imipramine, X2 (1, n = 67) = 6.415, p =
0.011. Regarding the 53 patients attaining therapeutic
plasma concentrations, the number of days until these
were reached differed significantly between the TCAs:
one-way ANOVA, F (24,28) = 3.619, p = 0.001.
Table 3 Recommendations on TCA dosing in treatment of unipolar MDD
Nortriptyline Clomipramine Imipramine Amitriptyline
Initial dose (mg/day) 25a, 25-50b,c or 50-75d 25-50b,c or 50-75f 25-50b,c 25-50a,b,c or 50h
EP†: 10-30d or 12.5-25b EP: 10f or 12.5-25b Outpatient: 25-75g CVD‡: 10-25h
Hospitalized: 75-100g EP: 10-25h or 12.5-25b
EP: 10g or 12.5-25b
Maintenance dose (mg/day) 50-200a,b, 75-200c 75-250b, 100-150c 75-300f or 100-300a,c 75-300b, 100-300a
or 100-150d or max. 250f Outpatient: 150-200g or max. 150h
Hospitalized: 100-200d EP: 30-50f Hospitalized: 200-300g
EP: 50-150d EP: 20-50g
Therapeutic plasma 50-150d or 70-170b,c,e 175–450§,c or 175–300§,b,c,e 80–200§,b,c,e
concentrations (ng/mL) 230–450§,b,e
† Elderly patients; ‡ Cardiovascular disease; § Sum of TCA and active metabolite
a American Psychiatric Association, 2010 [14]; b DGPPN, 2015 [13]; c WFSBP, 2013 [17]; d Mallinckrodt Pharmaceuticals, 2012 [23]; e Hiemke et al., 2018 [7]; f
Mallinckrodt Pharmaceuticals, 2014 [24]; g Excellium Pharmaceuticals Inc., 2012 [25]; h Sandoz, 2014 [26]











Female, n (%) 39 (52) 27 (51) 9 (50) 3 (75) 0.64
Age, mean (SD) 54.4 (16.6) 54.5 (17.1) 52.6 (15.1) 60.8 (18.9) 0.21
Hospitalized, n (%) 44 (59) 33 (62) 9 (50) 2 (50) 0.62
Psychotic depression, n (%) 16 (21) 12 (23) 4 (22) 0 (0) 0.56
TCA selection
Age > 65 years, n (%) 21 (28) 17 (32) 3 (17) 1 (25) 0.44
Comorbid anxiety‡, n (%) 7 (9) 5 (9) 2 (11) 0 (0) 0.79
TCA dosing
Initial dose (mg/day), mean (SD) 40.3 (19.5) 35.2 (14.1) 58.2 (23.4) 27.5 (16.6) 0.001**
Max. dose§ (mg/day), mean (SD) 105.1 (39.6) 90.3 (31.1) 133.3 (32.4) 175.0 (28.9) < 0.001**
TDM conducted§, n (%) 67 (89) 46 (87) 17 (94) 4 (100) 0.51
Therapeutic concentrations§, n (%) 53 (71) 42 (79) 9 (50) 2 (50) 0.040*
Pharmacogenetics¶, n (%) 5 (7) 5 (9) 0 (0) 0 (0) 0.33
* p = ≤0.05, ** p = ≤0.001 (two-tailed); † One-way ANOVA was used to compare age, initial and maximum dose. X2-tests were used to compare the other
variables; ‡ MDD with anxious distress (n = 1) or comorbid anxiety disorder (n = 6) [27, 28]; § Within two months since TCA initiation; ¶ Applied to optimize
TCA dosing
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Promotors and barriers regarding TCA prescription
Semi-structured interviews were conducted with 24 psy-
chiatrists. Their demographics are presented in Table 5.
Interviews lasted at least half an hour per interview. Four
psychiatrists treated elderly patients exclusively.
Factors influencing TCA selection
Factors influencing TCA selection by psychiatrists were
divided into several categories as presented in Fig. 1: pa-
tient’s preference, depressive symptoms, comorbidities,
treatment history, TCA related factors, psychiatrist re-
lated factors and contextual factors.
Patient’s preference All interviewed psychiatrists men-
tioned the importance of shared decision making: “It is
partly what you know from literature, but it is also mak-
ing a story together what is acceptable for both”.
Depressive symptoms All psychiatrists were more in-
clined to prescribe TCAs for severe, rather than for a
milder type of depression. Severe depression was de-
scribed as depression with vital signs, suicidality, psychotic
or catatonic features, psychomotor retardation or hope-
lessness. Most were more tempted to prescribe TCAs in
case of an endogenous, biological profile of depression,
characterized by recurrent episodes or a family history of
depression. In case of a more exogeneous profile, for in-
stance if psychosocial factors contributed significantly,
psychotherapy was favored. Many psychiatrists selected
nortriptyline, instead of other TCAs, if tiredness was a
major symptom of depression. Amitriptyline was preferred
in agitated depression or in case of prominent insomnia.
Comorbidities Comorbidities could hinder TCA selec-
tion in clinical practice. Relevant psychiatric comorbidi-
ties were bipolar disorder, a personality structure
causing or maintaining depression, which favored psy-
chotherapy, and manifest suicidality combined with
impulsivity, due to the risk of TCA auto-intoxications.
Comorbid anxiety disorder, OCD and obsessive-
compulsive personality disorder promoted clomipramine
instead of other TCAs. Relevant somatic comorbidities
were prolonged QT interval, cardiac disease,
hypotension, Parkinson’s disease, neurocognitive disor-
ders and a history of a myocardial infarction. Among the
TCAs, nortriptyline was preferred in case of relevant
somatic comorbidities and in elderly patients. Amitrip-
tyline or nortriptyline was generally prescribed in pa-
tients with comorbid pain syndrome.
Treatment history None of the psychiatrists preferred
TCAs as first-line treatment in the pharmacological
treatment of antidepressant-naïve patients with non-
psychotic MDD, both regarding hospitalized and outpa-
tients. Non-response to SSRIs, SNRIs and psychotherapy
promoted the choice for TCAs. TCAs were also more
frequently prescribed if they proved effective in a previ-
ous depressive episode or directly following to electro-
convulsive therapy (ECT). Discontinuation of SSRIs or
SNRIs due to adverse effects promoted a different SSRI
or SNRI. Also, use of monoamine oxidase (MAO) inhibi-
tors or QTc prolonging co-medications hindered TCA
selection.
TCA related factors A promotor for TCAs was that
therapeutic windows are defined, enabling psychiatrists to
dose on the basis of plasma concentrations. Many psychia-
trists confirmed that most patients experience more ad-
verse effects to TCAs than to SSRIs. A barrier for
amitriptyline and promotor for nortriptyline was that driv-
ing in the Netherlands is not allowed using amitriptyline,
but is allowed using nortriptyline after the first week of
treatment.
Psychiatrist related factors According to the inter-
viewed psychiatrists, the choice for an antidepressant is
influenced by training, experience, personal preference
and clinical setting. Some mentioned that psychiatrists
may have less experience with TCAs compared to mod-
ern antidepressants, possibly resulting in restraint to se-
lect them: “They only know the results of
epidemiological studies, not the pharmacological charac-
teristics. They can’t personalize their treatment”. Others
suggested that psychiatrists may accept partial remission
in treatment with SSRIs: “It’s one of the biggest pitfalls:
acceptance of partial remission. And it happens”. Fur-
thermore, psychiatrists may combine antidepressants or
augment antipsychotics prior to switching to TCAs.
Contextual factors Hospitalization facilitated TCA se-
lection. Hospital psychiatrists prescribed TCAs more fre-
quently, especially compared to private practice holders.
Table 5 Demographics of interviewed psychiatrists (n = 24)
Demographic Psychiatrists (n = 24)
Female, n (%) 10 (42)
Age, mean (range) 50.1 (34–68) years
Years of experience as psychiatrist, mean (range) 16.3 (1–38) years
Type of center
Academic hospital, n 4
General hospital, n 3
General psychiatric institution, n 14
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Several psychiatrists mentioned that the opinion of col-
leagues influenced their antidepressant selection. Many
used the Dutch Multidisciplinary guideline on treatment
of depressive disorders [10]. Some worked with local,
center-specific guidelines.
Factors influencing TCA dosing
Factors influencing TCA dosing were subdivided in
similar categories, as presented in Fig. 2: patient re-
lated factors, depressive symptoms, comorbidities, treat-
ment history, TCA related factors, psychiatrist
related factors and contextual factors. TCA dosing com-
prises prescription of the initial dosage and subsequent
dose-adjustment. In the interview optimal dose-
adjustment was defined as a limited amount of time
until the maintenance dose is attained combined with
exposing the patient to a minimum of adverse effects.
Patient related factors Most psychiatrists decided on
dosing together with the patient, which was thought to
promote confidence in treatment, adherence and treat-
ment success. Only one psychiatrist conducted pharma-
cogenetic testing regularly to optimize TCA dosing.
However, if available most psychiatrists would take the
metabolization phenotype into account.
Depression and comorbidities Depression severity did
not influence initial TCA dosing, although severe de-
pression incited faster dose-adjustment, particularly in
hospitalized patients. Some psychiatrists experienced
that patients may discontinue treatment during rapid
TCA up-titration and were more cautious in dose-
adjustment. Most psychiatrists dosed more gradually in
patients with comorbid anxiety disorder, as TCAs may
luxate anxiety, in patients with somatic comorbidities
and in elderly patients. Several psychiatrists specifically
emphasized the importance of adequate dose-
adjustment in elderly patients as they perceived that
TCA dosages were often not up-titrated until thera-
peutic plasma concentrations were reached: “Start low,
then go, but go all the way”.
Treatment related factors Previous TCA use promoted
faster dose-adjustment, especially if the required dose
was known. Most psychiatrists dosed more gradually if
patients experienced a lot of adverse effects to previous
antidepressants or if they used co-medications causing
potential drug-drug interactions with the prescribed
TCA.
The majority of interviewed psychiatrists perceived
problems in attaining therapeutic plasma concentrations,
although significantly less for nortriptyline compared to
Fig. 1 Most important factors influencing TCA selection by psychiatrists
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other TCAs. According to many psychiatrists, usual nor-
triptyline maintenance doses often correspond with
therapeutic plasma concentrations, while usual clomip-
ramine, imipramine or amitriptyline maintenance doses
frequently result in subtherapeutic plasma concentra-
tions. Hence, especially for clomipramine, imipramine
and amitriptyline, multiple dose-adjustments were often
necessary to attain therapeutic plasma concentrations.
A barrier concerning imipramine was that tablets of
max 25mg are available in the Netherlands requiring pa-
tients to use many tablets per day, which was thought to
hinder adherence.
Psychiatrist related factors According to the inter-
viewed psychiatrists, dosing was influenced by training,
knowledge and experience. Most psychiatrists applied
TDM within the first 2 weeks of treatment: “I always
monitor plasma concentrations, since the initial dosage
does mostly not result in therapeutic plasma concentra-
tions”. Some increased the dose in expectation of the re-
sult: “I measure plasma concentrations and increase the
dose directly. If plasma concentrations are too high, I
decrease the dose afterwards”. Others measured plasma
concentrations less frequently: “I dose on the basis of
the clinical picture. Measuring plasma concentrations is
rather out of frustration”.
Contextual factors Many psychiatrists highlighted the
importance of effective collaboration with other health
care professionals. Several perceived arranging ECG re-
cordings and TDM as time consuming, depending on
the local situation. According to multiple psychiatrists,
an outpatient setting could hinder dose-adjustment as
psychiatrists see outpatients less frequently. For TCA
dosing, most psychiatrists used the Dutch Multidiscip-
linary Guideline on treatment of depression [10, 18] and
the online Dutch Pharmacotherapeutic Compass [31].
Several psychiatrists mentioned that concise instructions
concerning TCA up-titration, TDM and pharmacogenet-
ics were lacking, potentially leading to inconsistencies in




In this study we present a comprehensive evaluation of
TCA prescription for MDD, focusing on Dutch psychia-
trists. Our evaluation of selected guidelines demon-
strated that only for subgroups of MDD patients is
specified whether a TCA should be prescribed. Also, if a
TCA is recommended, only for subgroups of patients is
specified which TCA should be prescribed. Current
practice guidelines provided little direction on how
TCAs should be up-titrated in an effective, tolerable
Fig. 2 Most important factors influencing TCA dose-adjustment by psychiatrists
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way, and what role TDM and pharmacogenetics should
play herein. Our findings are in line with several reviews
on antidepressant prescribing guidelines, reporting that
these are partially indirective and inconsistent with each
other, which can be partially accounted for by limited
evidence from clinical trials [32–34].
Health records indicated that Dutch psychiatrists pre-
ferred nortriptyline over other TCAs in treatment of
MDD. Most analyzed patients reached therapeutic
plasma concentrations within 2 months of TCA use. Pa-
tients who attained therapeutic plasma concentrations
reached them on average after 19.6 days. Time until at-
tainment of therapeutic TCA plasma concentrations in a
naturalistic setting has not been reported previously. Pa-
tients treated with nortriptyline reached therapeutic
plasma concentrations faster compared to patients using
clomipramine or imipramine.
Semi-structured interviews revealed differences be-
tween psychiatrists regarding the position of TCAs in
treatment of MDD and dose-adjustment. Hospital psy-
chiatrists were the most inclined to prescribe TCAs and
private practice holders the least, possibly because of a
difference in patient populations and ease of monitoring
the patient. Many psychiatrists experienced barriers in
TCA dose-adjustment, although significantly less for
nortriptyline compared to other TCAs. Important bar-
riers were adverse effects hindering dose up-titration,
managerial problems related to TDM and usual main-
tenance doses not corresponding with therapeutic
plasma concentrations.
Guideline adherence
A comparison between the Dutch guideline [10, 18] and
clinical practice, i.e. information provided by health re-
cords and interviews, showed that the guideline was not
consistently followed. Despite the guideline presenting
TCAs as first-line treatment option, all psychiatrists se-
lected TCAs as second- or third-line antidepressants,
also in hospitalized patients. Health records and inter-
views demonstrated that TDM is generally applied
within the first weeks of treatment to guide dose-
adjustment, whereas the guideline advises TDM only in
case of non-response [10] or in elderly patients with se-
vere MDD [18].
Several factors promoted TCA selection in clinical
practice but were not consistently mentioned in the
guidelines. For instance, severe depression promoted se-
lection of TCAs by psychiatrists in line with several
studies suggesting that TCAs are more effective than
SSRIs in treatment of severe melancholic depression
[35–37]. However, only the WFSBP guideline considered
depression severity explicitly, presenting TCAs as first-
line antidepressants for severe but not for milder depres-
sion [17]. In accordance with most selected guidelines,
the interviews with psychiatrists suggested that nortrip-
tyline was the preferred TCA in elderly patients and clo-
mipramine in patients with comorbid anxiety disorders,
although the latter could not be confirmed by our ana-
lysis of health records, possibly due to a limited number
of patients with comorbid anxiety.
The Dutch guideline did not consider pharmacogenet-
ics, which may be explained by its publication date (2013)
[10]. Nowadays, several genotype-informed dosing direc-
tions are available, but these are not embedded in general
antidepressant prescribing guidelines [8, 38]. The inter-
views suggested that separate guidelines for different as-
pects of TCA dosing, e.g., pharmacogenetics and TDM,
may promote heterogeneity in clinical practice.
Strengths and limitations
An important strength of this study is that different
methods were combined. Health records were selected
randomly, divided over five centers in the Netherlands.
Different types of centers were included. Moreover, the
interviewed psychiatrists were carefully selected to repre-
sent Dutch psychiatrists. A limitation is that we reviewed
a relatively small number of guidelines and health re-
cords, although representative for the Netherlands. Also,
we interviewed only psychiatrists who were used pre-
scribing TCAs. Psychiatrists prescribing TCAs less often
and other health care professionals may perceive differ-
ent promotors and barriers influencing TCA
prescription.
Conclusions
Today, there is considerable variation in guidelines and
clinical practice regarding TCA prescription for MDD.
This study confirms that TCAs are generally prescribed
as a later step in the pharmacological treatment of
MDD, but also that the present-day position of TCAs in
treatment of MDD and optimal dosing strategies require
further elaboration. In clinical practice, the choice for
TCAs was often motivated by guideline directions but
was also strongly guided by preferences of patients and
psychiatrists, based on a variety of reasons. Health re-
cords showed that TDM was frequently applied and that
most patients attained therapeutic plasma concentra-
tions within the first two months of treatment. Yet,
many psychiatrists perceived barriers in dose-
adjustment, although clearly less for nortriptyline com-
pared to other TCAs. To promote consistency in clinical
practice we recommend development of an up-to-date
guidance integrating TCA selection and dosing, includ-
ing the roles of TDM and pharmacogenetics, if possible
at a European level. Such a guideline is currently lacking
and would contribute to optimized TCA prescription,
whereby efficacy, safety and tolerability may be
increased.
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